IB Net Payout Yields Model

Hims & Hers Health: Roller Coaster Gift

 

  • Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target.
  • Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years.
  • The stock market over reacted to planned stock sells by the CEO.
  • Current weakness in HIMS shares presents a buying opportunity, with the stock trading at just 4x projected 2026 sales and robust long-term potential.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios. Learn More »
Hims & Hers Health, Inc. (NYSE:HIMS) launched a new product to market excitement, yet the stock ended last week lower due to confusion related to the CEO. The online health and wellness platform continues to build out a strong lineup of new health products contributing to the expected 2030 revenue target of $6.5 billion. My investment thesis remains ultra Bullish on the stock, especially after the recent dip while the business continues to expand with multiple new product launches in the last month.


Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Popular posts from this blog

Stat of the Day: VXO hits 45 again

Nextdoor: Next Step Up

Baidu: Historical Support At $80